Medivir (MVIR) Investor presentation summary

Market opportunity and disease landscape

• 45% of US adults are obese, with over 25% having fatty liver disease, which increases liver cancer risk 17-fold.

• The global second-line hepatocellular carcinoma (2L HCC) market is projected to grow from $2.8bn in 2024 to $4.0bn by 2030, driven by rising HCC incidence and longer treatment durations.

• HCC cases are expected to increase by 122% in the US and 82% in China by 2030, mainly due to fatty liver disease.

Fostrox mechanism and clinical profile

• Fostrox is the first oral, liver-targeted treatment for advanced HCC, designed to selectively kill tumor cells while sparing healthy liver cells.

• The prodrug is activated by liver enzymes, ensuring tumor-selective delivery and minimizing harm to healthy tissue.

Clinical trial results and safety

• In a global phase 1b/2a study, fostrox + Lenvima achieved a median time to progression (TTP) of 10.9 months, significantly longer than Lenvima monotherapy and other 2L HCC treatments (~3.5-5.4 months).

• The combination showed an objective response rate (ORR) of 24% and a disease control rate (DCR) of 81%.

• Liver function remained stable during treatment, as indicated by ALT, AST, and ALBI score monitoring.